tbuckley/cabot-search huggingface dataset:
Abstract 14072: Hemodynamics of Fontan Failure: Role of Pulmonary Vascular Disease
Authors: Alexander C Egbe, Arooj Khan, Heidi Connolly, Sana Khan, Barry Borlaug
Journal: Circulation (2017)

Background: Fontan failure remains important in the current era but the underlying hemodynamic mechanism for Fontan failure is not well understood Methods: Retrospective review of adult Fontan patients who underwent cardiac catheterization at Mayo Clinic,1990-2015. Patients were divided into 2 groups: Group 1: patients with high pulmonary vascular resistance index (PVRI) > 2 WU*m2 and low cardiac index (CI) < 2.5 L/min/m2; Group 2: PVRI ≤2 WU*m2 and CI ≥ 2.5 L/min/m2. The study hypothesis was that the combination of elevated PVRI and low CI would be associated with Fontan failure, defined by the composite of all-cause mortality, listing for heart transplantation, or initiation of palliative care. Result: Study cohort comprised of 261 patients; age 26±3years, men 146 (56%), atriopulmonary Fontan 144 (55%) The mean PVRI was 2.0±0.8 WU*m2 and the median CI was 2.8 (1.9-3.6) L/min/m2. Group 1 had 79 (30%) patients, and Group 2 had 182 (70%) patients. There were 69 (26%) cases of Fontan failure during follow-u...
SAT-131-The impact of sustained virological response on the criteria used to rule out high risk esophageal varices in HCV-related compensated advanced chronic liver disease
Authors: Giulia Tosetti, Pietro Soru, Vincenzo La Mura, Elisabetta Degasperi, Roberta D’Ambrosio, Elena Arsie, Marta Borghi, Roberta Soffredini, Massimo Primignani, Pietro Lampertico
Journal: Journal of Hepatology (2019)
SAT-244-Mixed cryoglobulinemia patients with persisting symptoms after SVR are characterized by B-cell clonality markers
Authors: Serena Lorini, Laura Gragnani, Veronica Santarlasci, Monica Monti, Umberto Basile, Luisa Petraccia, Francesco Madia, Silvia Marri, Lorenzo Martini, Eleonora Carradori, Adela Xheka, Patrizio Caini, Adriano Pellicelli, Lorenzo Cosmi, Francesco Annunziato, Anna Linda Zignego
Journal: Journal of Hepatology (2019)
Domestic Responsibilities of Physician Mothers
Authors: Julie Ann Freischlag
Journal: JAMA Surgery (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Surgery HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Surgery journal
Annals Story Slam - Oh, My Wandering Mind
Authors: Bielose C. Konwe
Journal: Annals of Internal Medicine (2019)

Web Exclusives7 May 2019Annals Story Slam - Oh, My Wandering MindFREEBielose C. Konwe, MDBielose C. Konwe, MDSearch for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/W19-0005 SectionsAboutVisual Abstract ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Video. Annals Story Slam - Oh, My Wandering Mind "Oh, My Wandering Mind," by Dr. Bielose Konwe (Duration 6:30)Building on the popular Annals feature “On Being a Doctor,” storytellers share stories about the experience of doctoring on video.For more videos from and information on Annals Story Slam, visit go.annals.org/StorySlam. Comments0 CommentsSign In to Submit A Comment Author, Article, and Disclosure InformationAffiliations: This article was published at Annals.org on 12 April 2019. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 7 May 2019Volume 170, Issue 9Page: SS1 ePublished: 12 April 2019 Issue Published: 7 May 2019 Copyright & PermissionsCopyright © 2019 by American College of Physicians. All Rights Reserved.Loading ...
Facilitating Conversion of Implantable Cardioverter-Defibrillator Therapy to Pacing Only—Time to Adapt
Authors: Daniel B. Kramer, Alfred E. Buxton, Peter J. Zimetbaum
Journal: JAMA Cardiology (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Cardiology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Cardiology journal
Abstract 20647: Sudden Cardiac Death After Atrial Switch Repair for D-Transposition of the Great Arteries: A Systematic Review and Meta-Analysis
Authors: Prashanth Venkatesh, Anna M Maw, Arthur T Evans, Agam D Patel, Raymond A Pashun, Kana Fujikura, Irfan Minhas, Luke K Kim, Rajesh V Swaminathan, Dmitriy N Feldman, Robert M Minutello, Geoffrey Bergman, S C Wong, Emile Bacha, Harsimran S Singh
Journal: Circulation (2016)

Introduction: Patients who underwent atrial switch repair with the Mustard or Senning procedure for D-transposition of the great arteries (D-TGA) in childhood are at risk of late sudden cardiac death (SCD). The existing literature in this area is heterogeneous, consisting of individual cohorts with considerable controversy as to the predictors of SCD in this population. Methods: A systematic review and meta-analysis was performed of published and unpublished studies documenting long-term mortality of patients undergoing the Mustard or Senning procedure with a mean or median follow-up of at least 10 years. Data describing SCD was extracted. Multiple studies from the same center as well as studies describing patients with palliative atrial switch procedures were excluded. Results: A total of 23 studies comprising 3803 patients met criteria. The median annual incidence of SCD was 0.22% (IQR 0.16-0.35), with SCD being the single most common cause of late mortality across cohorts. Using a random effects model,...
PS-178-Simplified monitoring for hepatitis C virus treatment with glecaprevir plus pibrentasvir: the SMART-C study
Authors: Gregory Dore, Jordan Feld, Alexander Thompson, Marianne Martinello, Andrew Muir, Kosh Agarwal, Beat Müllhaupt, Heiner Wedemeyer, Karine Lacombe, Gail Matthews, Michael Schultz, Gerard Estivill Mercade, Danny Kho, Ecaterina Filep, Kathy Petoumenos, Pip Marks, Fernando Tatsch, Ana Gabriela Pires dos Santos, Edward Gane
Journal: Journal of Hepatology (2019)
Abstract 15710: Impact of Age on the Efficacy and Safety of Alirocumab in Patients With Heterozygous Familial Hypercholesterolemia
Authors: Henry N Ginsberg, Jaakko Tuomilehto, G Kees Hovingh, Bertrand Cariou, Raul D Santos, Alan S Brown, Santosh K Sanganalmath, Andrew T Koren, Desmond E Thompson, Frederick J Raal
Journal: Circulation (2017)

Background: Individuals with heterozygous familial hypercholesterolemia (HeFH) often require additional LDL-C lowering beyond that achieved with statins. The PCSK9 inhibitor alirocumab (ALI) was sh...
<i>KEAP1</i>-mutations in patients with non-small cell lung cancer (NSCLC).
Authors: Rieke Frank, Matthias Scheffler, Sebastian Yves Friedrich Michels, Anna Eisert, Rieke Fischer, Katharina Koenig, Sabine Merkelbach-Bruse, Monika Heidi Serke, Yon-Dschun Ko, Ulrich Gerigk, Thomas Geist, Lukas Carl Heukamp, Reinhard Büttner, Juergen Wolf
Journal: Journal of Clinical Oncology (2015)

8097 Background: Mutations in genes of the KEAP1-NFE2L2 pathway of patients with NSCLC are associated with an increased tumor growth, resistence towards cytostatic drugs and reduced survival rates. KEAP1 suppresses NFE2L2 under physiological conditions. Oxidative stress or electrophiles cause NFE2L2 to stabilize and translocate to the nucleus, resulting in the transcription of various cytoprotective genes. Mutations in KEAP1 are described for diverse tumor entities with a relatively high frequency causing an increased level of NFE2L2. This leads to resistance of cancer cells against anti-cancer drugs and irradation. This study was performed to characterize KEAP1-mutated NSCLC clinically and genetically. Methods: Tumor tissue collected from 446 patients within a regional screening network was analysed for KEAP1 mutations using next-generation sequencing (NGS). Clinical, pathological and genetic characteristics of these patients are described and compared with a control group of patients without KEAP1 mutation. Results: So far, we identified 33 patients with KEAP1 mutations. Among these we found 34 different mutations, of which the majority was not previously described. KEAP1 mutations were not restricted to a special exon. In 30 patients (90.9%), additional driver aberrations in KRAS, EGFR, FGFR1, FGFR3, STK11, ALK, DDR2, HRAS, BRAF, PIK3CA, PTEN, NFE2L2, EP300, TSC1, CREBBP, NRAS, MET and Her2 could be detected, as well as mutations and polymorphisms in TP53. KEAP1 mutations occurred in both genders (male/female ratio 3/1), in squamous-cell carcinoma (36.4%) and adenocarcinoma (60.6%) and were significantly associated with smoking. The prognostic and predictive impact of KEAP1 mutations in a prospective cohort will be presented. Conclusions: Our data suggest a role of KEAP1-mutations as a cofactor in addition to classical driver mutations underlying the malignant phenotype of lung cancer cells. So far, this is the largest cohort of patients with KEAP1-mutations analysed and described. Further survival and treatment analyses will reveal the role of these mutations for the outcome of these patients.
SAT-470-Circulating levels of soluble urokinase plasminogen activator receptor (suPAR) predict outcome after resection of cholangiocarcinoma
Authors: Sven Loosen, Frank Tacke, Annemarie Breuer, Jakob Kather, Thomas Longerich, Alexander Koch, Christian Trautwein, Christoph RODERBURG, Ulf Neumann, Tom Lüdde
Journal: Journal of Hepatology (2019)
Higher in vivo Cortical Intracellular Volume Fraction Associated with Lithium Therapy in Bipolar Disorder: A Multicenter NODDI Study
Authors: Samuel Sarrazin, Cyril Poupon, Achille Teillac, Jean-François Mangin, Mircea Polosan, Pauline Favre, Charles Laidi, Marc-Antoine D'Albis, Marion Leboyer, Pierre-Marie Lledo, Chantal Henry, Josselin Houenou
Journal: Psychotherapy and Psychosomatics (2019)

&lt;b&gt;&lt;i&gt;Background:&lt;/i&gt;&lt;/b&gt; MRI studies in patients with bipolar disorder have suggested that lithium is associated with grey matter increases that may underlie its therapeutic effects. However, the relationship between grey matter volume and cellular microstructural changes is not straightforward, as modifications of different cellular compartments of grey matter may be involved. &lt;b&gt;&lt;i&gt;Objectives:&lt;/i&gt;&lt;/b&gt; Our aim was to test the hypothesis that dendritic density is higher in patients undergoing lithium therapy than in patients without lithium, using advanced modelling of water diffusion investigated with MRI. &lt;b&gt;&lt;i&gt;Method:&lt;/i&gt;&lt;/b&gt; We included 41 patients and 40 controls matched for age and gender from two sites. All subjects underwent 3T MRI with 3 shells of diffusion. We used neurite orientation dispersion and density imaging to compare the grey matter neurite density between patients undergoing lithium therapy or not and control subjects. &lt;b&gt;&lt;i&gt;Results:&lt;/i&gt;&lt;/b&gt; We found a significant group effect in the left prefrontal region (&lt;i&gt;p&lt;/i&gt; = 0.001, Bonferroni corrected): patients without lithium had a lower frontal neurite density than controls (&lt;i&gt;p&lt;/i&gt; = 0.009), while those on lithium had a higher mean neurite density than those without (&lt;i&gt;p&lt;/i&gt; &amp;#x3c; 0.001). Patients on lithium were not different from controls (&lt;i&gt;p&lt;/i&gt; = 0.08). &lt;b&gt;&lt;i&gt;Conclusions:&lt;/i&gt;&lt;/b&gt; This is the first study to report in vivo evidence of preserved neurite density of the prefrontal cortex in humans associated with lithium intake. Changes of intracellular volume fraction are thought to reflect changes of grey matter microstructural organization. This reinforces the hypothesis of lithium having a positive effect on the neuronal compartment in humans.
Centrosome amplification and prognosis in breast cancer.
Authors: Ryan Austin Denu, Mark E. Burkard
Journal: Journal of Clinical Oncology (2015)

11036 Background: Centrosome amplification (CA) has been reported in all human cancers and is thought to result in aneuploidy and chromosomal instability (CIN). CA is associated with deleterious clinical factors such as higher grade and stage, but these reports have not shown how CA affects survival. Here we analyzed centrosome abnormalities in a cohort of 362 patients. Methods: A tissue microarray was constructed using triplicate punch biopsies from each patient. Centrosomes were recognized by immunohistochemistry as the overlap of pericentrin and polyglutamylated tubulin, which represent pericentriolar material (PCM) and centriole markers, respectively. We assessed centrosome number, size, shape, and clustering in at least 30 cells from 3 different regions of each patient’s tumor. Ploidy and CIN were assessed using 6-chromosome FISH. Survival was analyzed using the Kaplan-Meier method and Cox proportional hazards modeling. Correlations were assessed using Spearman’s rank correlation coefficient. Results: CA was associated with worse overall survival, both all-cause and breast cancer-specific mortality, as well as recurrence-free survival. Further, greater centrosome size and centrosome clustering were also associated with worse survival. CA was more pronounced in triple negative and HER2-positive subgroups, and also increased with increasing stage and histological grade. Cox proportional hazards modeling using CA, stage, grade, HER2 status, and hormone receptor status revealed that stage and hormone receptor status were the only independent predictors of survival in this cohort. Further, CA correlated with increased ploidy and chromosomal instability in these tumors. Lastly, the presence of acentriolar centrosomes was higher in cases of higher grade and stage. Conclusions: CA, centrosome clustering, and increased centrosome size are associated with worse survival and adverse clinical factors in breast cancer and provide important insight and possibly a direct biologic explanation for the clinical behavior of some aggressive cancers. The presence of acentriolar centrosomes was associated with higher grade and stage, which suggests that PCM fragmentation may be one cause of CA, particularly in more aggressive tumors.
Drug induced micellization into ultra-high capacity and stable curcumin nanoformulations: Physico-chemical characterization and evaluation in 2D and 3D in vitro models
Authors: Michael M. Lübtow, Lena C. Nelke, Julia Seifert, Johanna Kühnemundt, Gaurav Sahay, Gudrun Dandekar, Sarah L. Nietzer, Robert Luxenhofer
Journal: Journal of Controlled Release (2019)
PS-080-Short term RNA interference therapy in chronic hepatitis B using JNJ-3989 brings majority of patients to HBsAg &lt; 100 IU/ml threshold
Authors: Man-Fung Yuen, Stephen Locarnini, Tien Huey Lim, Simone STRASSER, William Sievert, Wendy Cheng, Alex Thompson, Bruce Given, Thomas Schluep, James Hamilton, Gavin Cloherty, Danny Wong, Christian Schwabe, Kathy Jackson, Carlo Ferrari, Ching Lung Lai, Robert G. Gish, Edward Gane
Journal: Journal of Hepatology (2019)
THU-388-Annual healthcare costs double for non-alcoholic fatty liver disease/non-alcoholic steatohepatitis patients who progress to advanced liver disease: A multivariable analysis of German real-world data
Authors: Ali Canbay, Nandita Kachru, Dominic Meise, Jennifer Scarlet Haas, Ahmet Burak Ozbay
Journal: Journal of Hepatology (2019)
PS-206-Patterns and predictors of alcohol use after early liver transplant for alcoholic hepatitis
Authors: Brian Lee, Mary Rinella, Gene Im, John Rice, Oren Fix, George Therapondos, Hyosun Han, David Victor, Ethan Weinberg, Cristine Hsu, Michael Voigt, Haripriya Maddur, Sheila Eswaran, David Foley, R. Mark Ghobrial, Lisanne Dinges, Jennifer Dodge, Neil Mehta, Michael R. Lucey, Norah Terrault
Journal: Journal of Hepatology (2019)
TCTAP C-002 The Nightmare of Rescue PCI In Coronary Artery Ectasia: A Resistant Thrombus That Migrating Proximally in the RCA - "The Clock is Ticking"
Authors: Patrick W.J. Tiau, Chee Ken Choor, Hamat Hamdi Che Hassan, Oteh Maskon, Shathiskumar Govindaraju, Shawal Faizal Mohamad, Chen Fei Ng
Journal: Journal of the American College of Cardiology (2019)
Annals Story Slam - Against All Odds
Authors: Misa Stroker
Journal: Annals of Internal Medicine (2019)

Web Exclusives7 May 2019Annals Story Slam - Against All OddsFREEMisa Stroker, MDMisa Stroker, MDSearch for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/W19-0011 SectionsAboutVisual Abstract ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Video. Annals Story Slam - Against All Odds "Against All Odds," by Dr. Misa Stroker (Duration 7:05)Building on the popular Annals feature “On Being a Doctor,” storytellers share stories about the experience of doctoring on video.For more videos from and information on Annals Story Slam, visit go.annals.org/StorySlam. Comments0 CommentsSign In to Submit A Comment Author, Article, and Disclosure InformationAffiliations: This article was published at Annals.org on 12 April 2019. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 7 May 2019Volume 170, Issue 9Page: SS1 ePublished: 12 April 2019 Issue Published: 7 May 2019 Copyright & PermissionsCopyright © 2019 by American College of Physicians. All Rights Reserved.Loading ...
Species distribution and antifungal susceptibility of 358 Trichosporon clinical isolates collected in 24 medical centres
Authors: E.C. Francisco, J.N. de Almeida Junior, F. de Queiroz Telles, V.R. Aquino, A.V.A. Mendes, M.G.M. de Andrade Barberino, P. de Tarso O. Castro, T. Guimarães, R.C. Hahn, A.C.B. Padovan, G.M. Chaves, A.L. Colombo
Journal: Clinical Microbiology and Infection (2019)

To provide species distribution and antifungal susceptibility profiles of 358 Trichosporon clinical isolates collected from 24 tertiary-care hospitals.Species identification was performed by sequencing the IGS1 region of rDNA. Antifungal susceptibility testing for amphotericin B, fluconazole, voriconazole and posaconazole followed the Clinical and Laboratory Standards Institute reference method. Tentative epidemiologic cutoff values (97.5% ECVs) of antifungals for Trichosporon asahii were also calculated.Isolates were cultured mostly from urine (155/358, 43.3%) and blood (82/358, 23%) samples. Trichosporon asahii was the most common species (273/358, 76.3%), followed by T. inkin (35/358, 9.7%). Isolation of non-T. asahii species increased substantially over the last 11 years [11/77 (14.2%) from 1997 to 2007 vs. 74/281, (26.3%) from 2008 to 2018, p0.03]. Antifungal susceptibility testing showed high amphotericin B minimum inhibitory concentrations against Trichosporon isolates, with higher values for T. faecale. The ECV for amphotericin B and T. asahii was set at 4 μg/mL. Among the triazole derivatives, fluconazole was the least active drug. The ECVs for fluconazole and posaconazole against T. asahii were set at 8 and 0.5 μg/mL, respectively. Voriconazole showed the strongest in vitro activity against the Trichosporon isolates; its ECV for T. asahii was set at 0.25 μg/mL after 48 hours' incubation.Trichosporon species diversity has increased over the years in human samples, and antifungal susceptibility profiles were species specific. Trichosporon asahii antifungal ECVs were proposed, which may be helpful to guide antifungal therapy.
Radiographic patterns of progression in patients with EGFR-mutant NSCLC undergoing EGFR TKI therapy.
Authors: Nicole Brenner, Bruno R. Bastos
Journal: Journal of Clinical Oncology (2015)

e19108 Background: There is paucity of data about the radiographic patterns of progression in patients with EGFR mutant NSCLC undergoing EGFR TKI therapy. The progression may be linked to evolutional changes of the EGFR in the cancer cells (Tumor Darwinism). The evaluation of this pattern might provide additional insight into the tumor biology of the disease and also may serve as a guide for additional biopsies and therapeutic strategies. Methods: Twenty-one patients with advanced NSCLC undergoing EGFR TKI therapy at our institution were included in this study. An IRB-approved retrospective review of radiographic data was performed and assessed for progression at the primary and metastatic sites. Results: The patient population in this study was 47.6% male, with a median age 62 +/-10.1 years. The EGFR mutations were present on exons 18 (14.3%), 19 (47.6%), and 21 (38.1%). The initial sites of progression after initiation of EGFR TKI therapy were: primary site (4.7%), metastases (81.0%), and both primary and metastatic sites (14.3%). Of the progressed metastatic lesions, the most common sites were new pulmonary lesions (50.0%), osseous lesions (40.0%), and lymph nodes (30.0%). Conclusions: In our series, patients undergoing therapy with EGFR TKI tend to recur more at the metastatic sites than at the primary tumor site. This may be relevant for diagnostic and therapeutic strategies through the incorporation of additional biopsies to understand tumor biology and local therapies to treat distant sites of progression.
SAT-490-No impact of direct-acting antivirals on recurrent hepatocellular carcinoma tumour growth in the ANRS CO22 Hepather Cohort
Authors: Anais Vallet Pichard, Correas Jean Michel, Dorival Celine, Fabien Zoulim, Albert Tran, Marc Bourliere, Paul Cales, Dominique Guyader, Jean-Pierre Bronowicki, Dominique Larrey, Vincent Leroy, Christophe Hezode, Veronique Loustaud-Ratti, Jérôme Gournay, Victor De Ledinghen, Tarik Asselah, Nathalie Ganne, Metivier Sophie, Olivier Chazouilleres, Didier Samuel, Isabelle Rosa, Philippe Mathurin, Helene Fontaine, Fabrice Carrat, Pol Stanislas
Journal: Journal of Hepatology (2019)